Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Drug Abuse Advisory Committee

Executive Summary

Status of Astra's Dalgan Injection (dezocine) postmarketing surveillance of abuse and diversion will be addressed at the Feb. 4 meeting. Panel also will discuss the abuse liability of Bristol- Myers Squibb's Stadol Nasal Spray (butorphanol tartrate). On Feb. 5, the committee will address guideline development for assessing abuse liability of drugs and the status of guideline development for medications to treat drug dependence and abuse. Committee will meet at 9 a.m. both days at FDA's Parklawn building in conference rooms D & E.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS018623

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel